Dacomitinib
Drug for the treatment of lung carninoma
- US DailyMed: Dacomitinib
administration
- L01EB07 (WHO)
- (2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
- 1110813-31-4
Y
- 11511120
- 7422
- DB11963
- 9685914
- 2XJX250C20
- D09883
- as salt: D10514
- CHEBI:132268
- ChEMBL2105719
- 1C9 (PDBe, RCSB PDB)
- DTXSID50149493
- Interactive image
- COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
- InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+
- Key:LVXJQMNHJWSHET-AATRIKPKSA-N
Dacomitinib, sold under the brand name Vizimpro, is a medication for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.[3]
Dacomitinib has advanced to several Phase III clinical trials.[when?] The January 2014 results of the first trials were disappointing, with a failure to meet the study goals.[4][5][6] Additional Phase III trials are ongoing[when?].[4]
In 2017, results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.[7]
Dacomitinib was approved for medical use in the United States in September 2018,[8] in Japan in 2019, and in the European Union in 2019,[9] for the treatment of non-small cell lung cancer with epidermal growth factor receptor (EGFR) gene mutation.
References
- ^ "Vizimpro Product information". Health Canada. 25 April 2012. Retrieved 29 May 2022.
- ^ "Summary Basis of Decision (SBD) for Verzenio". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ "Dacomitinib". NCI Drug Dictionary. National Cancer Institute, U.S. Department of Health and Human Services.
- ^ a b Chustecka Z (27 January 2014). "Dacomitinib Fails in Pretreated Non-small Cell Lung Cancer". Medscape.
- ^ Taylor P (28 January 2014). "Blow to Pfizer as dacomitinib fails in lung cancer trials". pmlive.com.
- ^ "Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer". Pfizer Press Release. 27 January 2014.
- ^ Smith M (6 June 2017). "Dacomitinib Sets PFS Record in Phase III NSCLC Trial". MedPage Today.
- ^ Shirley M (December 2018). "Dacomitinib: First Global Approval". Drugs. 78 (18): 1947–1953. doi:10.1007/s40265-018-1028-x. PMID 30506139. S2CID 54034570.
- ^ "Vizimpro EPAR". European Medicines Agency (EMA). 5 June 2019. Retrieved 13 December 2019.
External links
- "Dacomitinib". Drug Information Portal. U.S. National Library of Medicine.
- v
- t
- e
| Receptor tyrosine kinase |
|
|---|---|
| Non-receptor |
- fusion protein against VEGF (Aflibercept)
- proapoptotic peptide against ANXA2 and prohibitin (Adipotide)
- exotoxin against IL-2 (Denileukin diftitox)
- mTOR inhibitors
- hedgehog inhibitors
- CDK inhibitors
- KRAS inhibitors
- Cabozantinib
- Capmatinib
- Entrectinib
- Erdafitinib
- Gilteritinib
- Larotrectinib
- Lenvatinib
- Masitinib
- Midostaurin
- Nintedanib
- Pazopanib
- Pemigatinib
- Pexidartinib
- Quizartinib
- Regorafenib
- Ripretinib
- Sorafenib
- Sunitinib
- Tebentafusp
- Tepotinib
- Vandetanib
- Venetoclax
Portal:
Medicine
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
